Concepedia

Author

Cezary Szczylik

Wojskowy Instytut Medycyny LotniczejORCID

Also Known As

A. Lopes, C Szczylik, C szczylik, C. SZCZYLIK, C. Szczylik, CEZARY SZCZYLIK, Cezary A. Szczylik, Cezary Szczylik, Cèzary A Szczylik, K. Yuce

469

Publications

38.2K

Citations

65

H-Index

133

Concepts

All Affiliations

Wojskowy Instytut Medycyny LotniczejInstitut Gustave RoussyMedical University of WarsawCleveland ClinicThe Maria Sklodowska-Curie National Research Institute of Oncology
CS

About

Cezary Szczylik is an author at Wojskowy Instytut Medycyny Lotniczej specializing in medicine, oncology, and urology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

44

93

14.3K

2

Health Sciences

21

28

2.4K

3

Engineering

1

1

40

4

Nursing

1

1

29

5

Public Health

1

1

22

Cezary Szczylik

×

157

Publications

35.1K

Citations

58

H-Index

YearCitations

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak,

New England Journal of Medicine

2007

5.7K

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

Bernard Escudier, Tim Eisen, Walter M. Stadler,

New England Journal of Medicine

2007

4.8K

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini, Elizabeth R. Plimack, V.P. Stus,

New England Journal of Medicine

2019

3.3K

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

Cora N. Sternberg, Ian D. Davis, Jozef Mardiak,

Journal of Clinical Oncology

2010

2.5K

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

Bernard Escudier, P. Koralewski, Alain Ravaud,

The Lancet

2007

2.2K

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak,

Journal of Clinical Oncology

2009

2.2K

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

Brian I. Rini, Bernard Escudier, Piotr Tomczak,

The Lancet

2011

1.8K

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

Bernard Escudier, Tim Eisen, Walter M. Stadler,

Journal of Clinical Oncology

2009

1.1K

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

Steffen Walter, Toni Weinschenk, Arnulf Stenzl,

Nature Medicine

2012

777

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

Martin Gore, Cezary Szczylik, Camillo Porta,

The Lancet Oncology

2009

590

Page 1